Machine Learning-Based QSAR Models for Discovery of Inhibitors Targeting Leishmania infantum Amastigotes

Background/Objectives: Leishmaniasis is a group of diseases caused by obligate intracellular parasites of the Leishmania genus and is classified by the World Health Organization as a category I neglected tropical disease. Leishmania infantum predominantly affects children under five years of age and shows an increasing incidence of cutaneous and visceral forms. The development of new therapeutic alternatives remains challenging, making in silico approaches valuable for accelerating antileishmanial drug discovery. This study aimed to identify new compounds with potential activity against Leishmania infantum amastigotes using artificial intelligence-based classification models. Methods: A curated database of compounds with reported biological activity was constructed. Molecular representation employed zero- to two-dimensional descriptors calculated with Dragon software (v 7.0.10). Unsupervised k-means cluster analysis was applied to define training and external prediction sets. Supervised models were developed on the WEKA platform using IBk, J48, multilayer perceptron, and sequential minimal optimization algorithms. Model performance was assessed through internal cross-validation and external validation procedures. Results: All models achieved classification accuracies above eighty percent for both training and prediction sets, indicating consistent predictive performance and good generalization ability. The validated models were applied to virtual screening of the DrugBank database and a collection of synthetic compounds. This screening campaign enabled the identification of one hundred twenty compounds with potential activity against the amastigote form of Leishmania infantum. Conclusions: Artificial intelligence-based QSAR models proved to be useful tools for prioritizing antileishmanial candidates. The integration of molecular descriptors, machine learning, and virtual screening offers an efficient strategy for drug discovery.